J
Joan H. Schiller
Researcher at University of Texas Southwestern Medical Center
Publications - 203
Citations - 11314
Joan H. Schiller is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 50, co-authored 203 publications receiving 10321 citations. Previous affiliations of Joan H. Schiller include National Foundation for Cancer Research & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris,Bruce E. Johnson,Lynne D. Berry,David J. Kwiatkowski,A. John Iafrate,Ignacio I. Wistuba,Marileila Varella-Garcia,Wilbur A. Franklin,Samuel J. Aronson,Pei Fang Su,Yu Shyr,D. Ross Camidge,Lecia V. Sequist,Bonnie S. Glisson,Fadlo R. Khuri,Edward B. Garon,William Pao,Charles M. Rudin,Joan H. Schiller,Eric B. Haura,Mark A. Socinski,Keisuke Shirai,Heidi Chen,Giuseppe Giaccone,Giuseppe Giaccone,Marc Ladanyi,Kelly Kugler,John D. Minna,Paul A. Bunn +28 more
TL;DR: The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.
Journal ArticleDOI
Lung cancer in never smokers — a different disease
TL;DR: In this article, the authors summarized the current knowledge of lung cancer and summarized the differences in the epidemiological, clinical and molecular characteristics of lung cancers arising in never smokers versus smokers, suggesting that they are separate entities.
Journal ArticleDOI
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
Alan Sandler,Robert Gray,J. Brahmer,A. Dowlati,Joan H. Schiller,Michael C. Perry,David H. Johnson +6 more
TL;DR: This randomized phase II trial of PC +/- bevacizumab (A) suggested improved activity for the combination of PCA when compared to PC alone, and multivariate analysis suggested squamous cell histology to be a significant risk factor.
Journal ArticleDOI
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
Suresh Ramalingam,Suzanne E. Dahlberg,Corey J. Langer,Robert Gray,Chandra P. Belani,J. Brahmer,Alan Sandler,Joan H. Schiller,David H. Johnson +8 more
TL;DR: In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC, and data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients.
Journal ArticleDOI
Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study
Fumiko Taguchi,Benjamin Solomon,Vanesa Gregorc,Heinrich Roder,Robert Gray,Kazuo Kasahara,Makoto Nishio,J. Brahmer,Anna Spreafico,Vienna Ludovini,Pierre P. Massion,Rafal Dziadziuszko,Joan H. Schiller,Julia Grigorieva,Maxim Tsypin,Stephen W. Hunsucker,Richard M. Caprioli,Mark W. Duncan,Fred R. Hirsch,Paul A. Bunn,David P. Carbone +20 more
TL;DR: This predictive algorithm based on matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) analysis of pretreatment serum could classify NSCLC patients for good or poor outcomes after treatment with EGFR TKIs.